OR-ASKNICELY
22.1.2020 21:07:07 CET | Business Wire | Press release
AskNicely , the customer experience platform for people-powered businesses, today announced the opening of its first European office in Amsterdam. The company is headquartered in Portland, Oregon and recently expanded its original office in Auckland, New Zealand.
“Amsterdam has become a hub for innovation,” said AskNicely co-founder and CEO Aaron Ward. “We recognize the potential of the city’s incredible talent pool, its world-class infrastructure, and the vibrant growth that has fueled the Amsterdam tech scene.”
The European office was added in response to customer demand, and to accelerate the company’s growth plans. In 2019, AskNicely raised $10 million in Series A funding and expanded on its core NPS software by launching the world’s first mobile customer experience coaching app, which helps companies consistently deliver on their brand promise by using real-time feedback to coach employees.
“I am delighted that AskNicely has chosen to set up its operations in the Netherlands and house its European activities here,” said Jeroen Nijland, Commissioner at the Netherlands Foreign Investment Agency (NFIA), from the Dutch Ministry of Economic Affairs. “AskNicely selecting the Netherlands is further proof that our country is very attractive for global businesses operating at the forefront of information and technological developments.”
The expansion is led by Vice President and General Manager Europe Kyle Bolster, who previously served as the first AskNicely sales leader and developed the company’s go-to-market strategy. Bolster plans to add up to a dozen Amsterdam employees across sales and customer success teams over the next year, focused on growth and providing exceptional service to existing European clients.
“We’re here to make our users’ lives easy. Thanks to AskNicely, we continuously improve our understanding of our users’ wants and needs,” said Ali Niknam, founder and CEO of European challenger bank bunq . “Welcome to Europe, AskNicely!”
AskNicely was founded in New Zealand in 2014, and the company’s 27-person technology and engineering staff remain based in Auckland. In 2017, AskNicely opened its first U.S. office in Portland, Oregon. Now the company’s official headquarters, its Portland office is home to 50 employees across marketing, sales, customer success, finance and human resources.
“We understand the importance of having localized staff to support our customers,” said Ward. “But we also prioritized choosing a European home that aligns with our company culture, which is very important to us. We chose to base our U.S. operations in Portland because of its commonalities with New Zealand: its culture, its affordable standard of living, and its ethos around customer experience. We feel that Amsterdam shares much of the same DNA and will be the ideal place for AskNicely to flourish in Europe.”
About AskNicely
AskNicely helps people-powered businesses deliver on their brand promise every day. Over a thousand companies around the globe trust AskNicely to understand and improve their customer experience, using the Net Promoter Score (NPS) framework for measurement and the principle of positive recognition for motivating front-line employee performance. Learn more at asknicely.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200122005751/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
